In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 8, 2010, Pages 3478-3480

  Pucci, Michael J ^a   Ackerman, Maria ^b   Thanassi, Jane A ^a   Shoen, Carolyn M ^b   Cynamon, Michael H ^b  

^a Achillion Pharmaceuticals   (United States)

^b SYRACUSE VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 702; GATIFLOXACIN; GYRASE INHIBITOR; ISOTHIAZOLE DERIVATIVE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DNA GYRASE; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLONES; THIAZOLES; TUBERCULOSIS;

EID: 77955347387     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00287-10     Document Type: Article

References (19)

1. Aubry, A., N. Vcziris, E. Camau, C. Truffot-Pernot, V. Jarlier, and L. M. Fisher. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
2. Aziz, M. A., A. Wright, A. Laszlo, A. De Muynck, F. Portaels, A. Van Deum, C. Wells, P. Nunn, L. Blanc, M. Raviglione, and WHO/International Union against Tuberculosis and Lung Disease Global Project on Anti-Tuberculosis Drug Resistance Surveillance. 2006. Epidemiology of antituberculosis drug resistance (the global project on anti-tuberculosis drug resistance surveillance): an updated analysis. Lancet 368:2142-2154.
3. Burman, W. J., S. Goldberg, J. L. Johnson, G. Muzanye, M. Engle, A. W. Mosher, S. Choudhri, C. L. Daley, S. S. Munsiff, Z. Zhao, A. Vernon, and R. E. Chaisson. 2006. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:331-338.
4. Centers for Disease Control and Prevention (CDC). 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
5. Cheng, J., J. A. Thanassi, C. L. Thoma, B. J. Bradbury, M. Deshpande, and M. J. Pucci. 2007. Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2445-2453. (Pubitemid 47047323)
6. Cynamon, M. H., M. Ackerman, M. J. Pucci, and C. Shoen. 2008. Abstr. 108th Gen. Meet. Am. Soc. Microbiol., abstr. A-002.
7. Espinal, M. A., A. Laszlo, L. Simonsen, F. Boulahbal, S. J. Kim, A. Reniero, S. Hoffner, H. L. Reider, N. Binkin, C. Dye, R. Williams, and M. C. Raviglione. 2001. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N. Engl. J. Med. 344:1294-1303.
8. Ferrero, L., B. Cameron, B. Manse, D. Langneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
9. Feuerriegel, S., H. S. Cox, N. Zarkua, H. A. Karimovich, K. Braker, S. Rusch-Gerdes, and S. Niemann. 2009. Sequence analyses of just four genes to detect extensively multidrug-resistant tuberculosis patients undergoing treatment. Antimicrob. Agents Chemother. 53:3353-3356.
10. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
11. Pucci, M. J., J. Cheng, S. D. Podos, C. L. Thoma, J. A. Thanassi, D. D. Buechter, G. Mushtaq, G. A. Vigliotti, Jr., B. J. Bradbury, and M. Deshpande. 2007. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens. Antimicrob. Agents Chem. 51:1259-1267.
12. Pucci, M. J., C. L. Thoma, S. D. Podos, J. Cheng, J. A. Thanassi, and B. J. Bradbury. 2008. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-2021.
13. Shah, N. S., A. Wright, G. H. Bai, L. Barrera, F. Boulahbal, N. Martin-Casabona, F. Drobniewski, C. Gilpin, M. Havelkova, R. Lepe, R. Lumb, B. Metchock, F. Portaels, M. F. Rodrigues, S. Rusch-Gerdes, A. Van Deun, V. Vincent, K. Laserson, C. Wells, and J. P. Cegielski. 2007. World-wide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13:380-387.
14. Shi, R., J. Zhang, C. Li, Y. Kazumi, and I. Sugawara. 2006. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 44:4566-4568.
15. Strahilevitz, J., Y. Onodera, and D. C. Hooper. 2006. An improved expression plasmid for affinity purification of Staphylococcus aureus gyrase A subunit. Protein Expr. Purif. 47:10-15.
16. Thanassi, J. A., J. Cheng, S. D. Podos, B. J. Bradbury, M. Deshpande, and M. J. Pucci. 2008. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-2022.
17. Vernon, A., and W. Burman. 2008. New treatment regimens for drug-sensitive tuberculosis: fluoroquinolones and enhanced rifamycins. Respirology 13:S116-S124.
18. Von Groll, A., A. Martin, P. Jureen, S. Hoffner, P. Vandamme, F. Portaels, J. C. Palomino, and P. A. daSilva. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
19. Zignol, M., M. S. Hosseini, A. Wright, C. L. Weezenbeek, P. Nunn, C. J. Watt, B. G. Williams, and C. Dye. 2006. Global incidence of multi-drug resistant tuberculosis. J. Infect. Dis. 194:479-485.